Technology


At the core of our technology is a proprietary endovascular implant engineered for precise placement in the descending abdominal aorta, adjacent to key arterial branches that supply vascularization to the stomach.

This location is critical, as it allows us to influence the body’s own physiological pathways involved in hunger signaling—without altering gastrointestinal anatomy or requiring permanent surgical modification.

Mechanism of Action


AVOS™ is designed to modulate blood flow to the gastric fundus, a region known to play a central role in the production of ghrelin, the body’s primary hunger hormone.

By carefully controlling perfusion in this region, our technology aims to reduce circulating ghrelin levels, leading to decreased appetite and caloric intake.